LENZ Therapeutics Inc. (LENZ)
undefined
undefined%
At close: undefined
30.97
-0.08%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia.

Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia.

The company is headquartered in Del Mar, California.

LENZ Therapeutics Inc.
LENZ Therapeutics Inc. logo
Country n/a
IPO Date Mar 22, 2024
Industry Biotechnology
Sector Healthcare
Employees n/a
CEO Evert B. Schimmelpennink

Contact Details

Address:
No Address available
No city data available,
Website n/a

Stock Details

Ticker Symbol n/a
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code n/a
CUSIP Number n/a
ISIN Number US52635N1037
Employer ID -
SIC Code n/a

Key Executives

Name Position
Evert B. Schimmelpennink President, Chief Executive Officer, Secretary & Director
Daniel R. Chevallard CPA Chief Financial Officer
Breianna Bowen Vice President of Human Resources
David Murphy Vice President of Marketing
Domenick Porfidia Vice President of Sales
James W. McCollum Co-Founder & Director
Marc G. Odrich M.D. Chief Medical Officer
Marvin J. Garrett Senior Vice President of Regulatory & Quality
Shawn Olsson Chief Commercial Officer

Latest SEC Filings

No SEC filings available.